Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer
Status: | Completed |
---|---|
Conditions: | Prostate Cancer, Cancer, Hospital |
Therapuetic Areas: | Oncology, Other |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 9/15/2017 |
Start Date: | August 24, 2012 |
End Date: | September 11, 2017 |
A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients With Prostate Cancer
This randomized phase III trial studies robotic assisted laparoscopic prostatectomy (RALP)
with pelvic drain placement to see how well it works compared to RALP without pelvic drain
replacement in reducing adverse events after surgery in patients with prostate cancer.
with pelvic drain placement to see how well it works compared to RALP without pelvic drain
replacement in reducing adverse events after surgery in patients with prostate cancer.
PRIMARY OBJECTIVES:
I. To determine if eliminating placement of a pelvic drain in patients during robotic
assisted laparoscopic prostatectomy (RALP) increases incidence of early postoperative adverse
events occurring within 90 days from prostatectomy, compared to patients who have a pelvic
drain placed during RALP.
SECONDARY OBJECTIVES:
I. To determine the incidence of early postoperative adverse events in patients with and
without a pelvic drain when adjustments to confounders associated with these events are made
(confounders: demographic, surgical and pathologic; age, body mass index [BMI], pathologic
stage, Gleason sum, extent of lymph node dissection).
II. To report peri-operative and postoperative outcomes, including but not limited to, length
of hospital stay, re-admissions, continence, potency and incidence of medical interventions
for patients with and without pelvic drain.
III. To compare early postoperative adverse event rates between patients with and without a
pelvic drain in patients who had extended pelvic lymph node dissection during RALP.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo RALP.
ARM II: Patients undergo RALP and placement of pelvic drain.
After completion of treatment, patients are followed up at 1 week and then 1, 3, 6, 9, and 12
months.
I. To determine if eliminating placement of a pelvic drain in patients during robotic
assisted laparoscopic prostatectomy (RALP) increases incidence of early postoperative adverse
events occurring within 90 days from prostatectomy, compared to patients who have a pelvic
drain placed during RALP.
SECONDARY OBJECTIVES:
I. To determine the incidence of early postoperative adverse events in patients with and
without a pelvic drain when adjustments to confounders associated with these events are made
(confounders: demographic, surgical and pathologic; age, body mass index [BMI], pathologic
stage, Gleason sum, extent of lymph node dissection).
II. To report peri-operative and postoperative outcomes, including but not limited to, length
of hospital stay, re-admissions, continence, potency and incidence of medical interventions
for patients with and without pelvic drain.
III. To compare early postoperative adverse event rates between patients with and without a
pelvic drain in patients who had extended pelvic lymph node dissection during RALP.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo RALP.
ARM II: Patients undergo RALP and placement of pelvic drain.
After completion of treatment, patients are followed up at 1 week and then 1, 3, 6, 9, and 12
months.
Inclusion Criteria:
- Male patients diagnosed with prostate cancer and scheduled to undergo RALP at City of
Hope National Medical Center
- Written informed consent obtained in accordance with institutional policies approved
by the U.S. Department of Health and Human Services
- Patients with prior transurethral resection and other prostate procedures are eligible
with the exception of the procedures indicated in the exclusion criteria
Exclusion Criteria:
- Non-compliance
- Prior radiotherapy to the pelvis or prostate
- Prior extensive pelvic surgery such as low anterior reception, abdomino-perineal
resection, or proctocolectomy continent stool pouch, or any other extensive
abdomino-pelvic surgery that would render the patient high-rick for complications as
deemed by the surgeon
- Demonstrated intra-operative anastomotic leakage when irrigated with 120 mL of normal
saline at the end of surgery
- Intra-operative injuries (for example: rectal injury)
- Inadequate hemostasis
We found this trial at
1
site
Duarte, California 91010
Principal Investigator: Jonathan Yamzon
Phone: 800-826-4673
Click here to add this to my saved trials